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Five species, Plasmodium malariae, Plasmodium ovale,
Plasmodium falciparum, Plasmodium vivax and, recently,
Plasmodium knowlesi, are recognized as natural malaria
parasites of humans. Due to its biology, P. vivax is the
most widely transmitted, occurring in temperate latitudes,
arid regions, at high altitude and in other environments
that are inhospitable to P. falciparum. Outside tropical
Africa, in Asia and the Western Pacific, and in Central
and South America, the most prevalent of these parasites
is P. vivax. By contrast, in sub-Saharan Africa, where
malaria transmission is otherwise more intense than any-
where else in the world, cases of P. vivax are greatly out-
numbered by those due to P. falciparum, and P. vivax is
almost undetectable in the local human populations. In
Brazil, the incidence of malaria is almost exclusively
(99.8%) of the cases restricted to the region of the Amazon
Basin, and is caused by three species of Plasmodium:
P. vivax (that accounts for 83.7% of the registered cases),
P. falciparum (causing 16.3% of the cases) and P. malariae
(rarely observed). No autochthonous transmission of
P. ovale and P. knowlesi occurs [1,2].
The gap in distribution of P. vivax in Africa compared
to the rest of the world is viewed as the consequence of
the lack of expression of the Duffy antigen on the red cells
(Duffy-negative phenotype), which mediates invasion of
reticulocytes by P. vivax, and is highly predominant in
the African populations in contrary to the observed in
European, Asian and American populations in whom the
Duffy-positive phenotype is more common. The pattern
of Duffy-blood group distribution is attributed to a posi-
tive natural selection, since P. vivax requires the presence
of Duffy antigen receptor for chemokines on the red blood
cells’ (RBC) surface to be able to invade cells and cause
disease (reviewed in [3-6]).
The Duffy blood group locus, at position q21–q25 on
chromosome 1 [7], is characterized by three main alleles:
FY*A, FY*B and FY* BES. The FY*A and FY*B alleles are
distinguished by a missense mutation, which results in a
single amino acid difference and gives the common Fy
(a+b-), Fy(a-b+) and Fy(a+b+) phenotypes [8-11]. The
FY*BES allele, which corresponds to the Fy(a-b-) sero-
logical phenotype (i e, the absence of Fy antigen), is due
to a T-33C point mutation on the FY*B gene promoter,
which abolishes the erythroid gene expression by
disrupting a binding site for the GATA-1 erythroid tran-
scription factor and results in the elimination of the
transcription of FY mRNA in RBCs, but not in other cell
types [12,13]. The same mutation associated with the
FY*A variant (FY*AES allele) was already identified at low
frequencies in individuals living in a P. vivax-endemic
region of Papua New Guinea [14,15].
Although there is a large body of evidence that states
that invasion of P. vivax requires the Duffy antigen, theuniversality of the specificity is certainly now under ques-
tion with recent reports that in some parts of the world
P. vivax infects and causes disease in Duffy-negative
people: in western Kenya [16], in the Western Brazilian
Amazon region [17,18], in Madagascar [19], in African
West Coast (Equatorial Guinea and Angola) [20], and
in Mauritania, north-west Africa [21]. These findings
reinforce the idea that this parasite is rapidly evolving,
being able to use other receptors than Duffy to invade the
erythrocytes, which may have an enormous impact in
P. vivax current distribution [20].
The aims of this study were to investigate the presence
of P. vivax infection in Duffy-negative individuals from
Anajás, State of Pará, an area of malaria transmission in
the Brazilian Amazonia, using an allele-specific primer
polymerase chain reaction (PCR) technique for Duffy
blood group genotyping, and conventional blood smear
light microscopy and a TaqMan-based real-time PCR
method to detect P. falciparum and P. vivax.Methods
Ethics statement
The study was approved by the Ethics Committee of
João de Barros Barreto Hospital, Federal University of
Pará, Belém, State of Pará, Brazil, and health authorities
from the municipal district of Anajás.Sampling
The samples for this study were collected in August
2009 in a cross-sectional study conducted in Anajás,
Archipelago of Marajó, State of Pará, Eastern Brazilian
Amazon (00°59'13''S; 49°56'24''W). Anajás was the mu-
nicipal district that presented the highest index of
malaria in the State of Pará in the year of 2009, with
26,043 positive cases in a population of 27,385 inhabi-
tants, resulting in an Annual Parasitic Index (IPA) of
951/1,000 inhabitants [22].
In total, 738 patients were examined, 339 of them
living in the city and 399 in two riverine communities in
rural Anajás (Vencedora, n=212 and Luciana, n=187).
Luciana village is located on the left bank of the
River Mocoões (0°50'27.81''S;49°50'9.14"W), about 25 km
downstream of the city of Anajás. Vencedora village
is located on the right bank of the Alto Rio Anajás
(0°58'52.26''S;49°58'08.33"W), about 5 km upstream from
the city of Anajás. The patients were clinically examined,
and 2 mL of blood were drawn for thick blood smears
preparation and for molecular diagnosis of malaria
infection. Microscopic parasitaemia examinations were
performed by three experienced malaria field microsco-
pists from the Federal University of Pará (UFPA) on
slides using the thick film method and the results were
reported as parasites/μL [23].
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DNA was extracted from 300 μL of EDTA-treated blood
using the NeoIsoColumn kit (One Lambda Inc., San Diego,
CA, USA) according to the manufacturer’s instructions.
DNA was eluted in 200 μL of elution buffer (provided with
the kit).
Real-time PCR
For real-time PCR, Primer Express software (Life
Technologies, Foster City, CA, USA) was used to design
specific primers (forward and reverse) targeting a
mitochondrial DNA (mtDNA) sequence common to all
Plasmodium spp, and TaqMan™ fluorescence-labelled
probes to hybridize differentially in P. vivax or P. falcip-
arum, enabling species identification. The following oli-
gonucleotides primers and probes were used: forward
5’-ACCTCCAGGCAAAGAAAATGAC-3’, reverse 5’-
GGCGAGAAGGGAAGTGTGTTT-3’ and probes 5’-
AACGGAATCAGTTAA-3’-FAM for P. vivax and
5’-ACGGAATCAATTAAC-3’-VIC for P. falciparum.
DNA templates were amplified in an Applied Bio-
systems 7500 analytical PCR system (SDS version 1.7).
Briefly, a 50 μL PCR mixture was performed using
20–100 ng/μL of purified DNA template, 25 mL of
TaqMan™ 2X (Life Technologies) universal PCR mas-
ter mix, and a final concentration of 300 nM of each
parasite species-specific primer and 200 nM of each
corresponding probe. Amplification and detection were
performed under the following conditions: 2 min at 50°C
to achieve optimal AmpErase uracil-N-glycosylase activity,
10 min at 95°C to activate the AmpliTaq Gold DNA poly-
merase, and 45 cycles of 15 sec at 95°C and 1 min at 60°C
using a 7500 Real-Time PCR System (Life Technologies,
Foster City, CA, USA). Each experiment included one re-
action mixture without DNA as a negative control.
DNA sequence analysis
The specificity of the assay was confirmed by sequencing
the PCR products from all positive samples using a Big
Dye terminator sequencing kit (Applied Biosystems) on
an ABI 3130 sequencer (Applied Biosystems) following
the manufacturer’s instructions. In samples with positive
results to P. falciparum, this procedure is particularly
necessary to exclude possible infections by P. malariae,
P. knowlesi and P. ovale, since the employed probe can
identify all these species. The sequences obtained were
aligned with those deposited in GenBank using the
BLAST (Basic Local Alignment Search Tool) program.
Duffy blood group genotyping
The samples were genotyped using an allele-specific pri-
mer polymerase chain reaction (PCR) technique described
by Olsson et al [24]. Amplification was performed for each
subject with sense primers corresponding to normal andGATA-1-mutated promoter sequence combined with anti-
sense primers that discriminate the FY*A and FY*B alleles
in four different combinations of primer pairs. PCR mix-
tures included 100 ng genomic DNA, 0.2 mM of each
primer, 100 mM of each dNTP, 1.5 mM MgCl2, and 0.5 U
AmpliTaq Gold polymerase (Perkin Elmer, USA) in the
AmpliTaq Gold buffer supplied by Perkin Elmer in a reac-
tion volume of 25 μL. Mixtures were incubated for 8 min
at 95°C, followed by 10 cycles of 94°C for 1 min and 69°C
for 1 min, 25 cycles of 94°C for 1 min, 64°C for 1 min and
72°C for 1 min, and a final incubation at 72°C for 10 min.
PCR products were separated electrophoretically using
1.5% agarose gel at 150 volts for 30 min and visualized
with SYBRW Safe DNA gel stain under UV excitation.
Statistical analysis
Statistical analysis was undertaken using χ2 analysis
to compare the proportions of Duffy genotypes alleles
among in P. vivax-infected patients and sympatric
malaria-exposed controls (P. falciparum-infected and
non-infected individuals).
Results
Both Duffy genotyping and Plasmodium species diagnostic
assays (qPCR-mtDNA method) were performed success-
fully for 678 individuals (330 urban, 166 of Vencedora and
182 of Luciana). Plasmodium spp. infection was detected
in 137 samples (20.2%), of which 57 (17.3%) urban, 25
(15.1%) of Vencedora and 55 (30.2%) of Luciana. Overall
prevalence of each Plasmodium species was 13.9%
(94/678) P. vivax, 5.8% (39/678) P. falciparum, and 0.6%
(4/678) P. vivax + P. falciparum. In all of the study sites
prevalence of P. vivax was the highest, ranging from
12.1% in urban patients to 17.6% in Villa Luciana. P. fal-
ciparum was found in only one patient of Vencedora
(0.6%), 16 (4.8%) patients and in 22 urban (12.1%) of
Luciana. Overall, 4.3% (29/678) were genotyped as Duffy-
negative (FY*BES/*BES) FY*BES/*BES and 95.7% (649/678)
were Duffy positive. Among Duffy-negative individuals
6.9% (2/29) were P. vivax PCR positive based on the
qPCR-mtDNA method, and among Duffy-positive 14.7%
(96/649) were P. vivax PCR positive. The two Duffy-
negative PCR positive for P. vivax were identified at
Luciana (2/22 infected individuals). The risk of Duffy-
negatives to experience a P. vivax blood stage infec-
tion was lower but not significantly different to that
of Duffy-positives (Odds ratio = 0.4460; 95% confi-
dence interval 0.1044 – 1.9060; P = 0.3983).
Moreover, among P. vivax-infected patients (94 P. vivax
mono-infections and four P. vivax/P. falciparum mixed
infections), 2.0% were Duffy-negative and the frequency of
the allele FY*BES in this group was 18.6%. Among P. falci-
parum-infected and non-infected individuals (sympatric
malaria-exposed controls, n = 584) 4.6% were Duffy-
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sample the frequency of allele FY*BES was 18.4%. No sig-
nificant differences were observed when comparing the
genotypic and allelic frequencies of the Duffy blood group
among Duffy-negative P. vivax-infected patients and
controls both the total sample and in each of the
three study sites, also suggesting no significant reduc-
tion of infection rates among the carriers of the
FY*BES allele (Tables 1 and 2).
Discussion
The prevalence of P. vivax and P. falciparum and Duffy-
blood group genotype distribution was studied in the
population of Anajás, State of Pará, an area of malaria
transmission in the Brazilian Amazonian, in order to ana-
lyse the presence of P. vivax infection in Duffy-negative
individuals.
Until recently, the Duffy-negative phenotype was seen
as giving complete protection against infection by P. vivax,
since this parasite requires the presence of Duffy antigen
receptor for chemokines on the RBC surface to be able to
invade cells and cause disease. However, the universalityTable 1 Duffy genotyping and Plasmodium species diagnosis
Place Duffy genotypes Co
























*patients infected with P. falciparum and non-infected individuals.of this specificity has been questioned by recent reports
that P. vivax infects and causes disease in Duffy-negative
people in some parts of the world [16-21].
In this study, 6.9% (2/29) of the Duffy-negative subjects
were diagnosed as P. vivax-infected, a finding that con-
firms previous reports in patients from Rondonia, western
Brazilian Amazon [17,18], as well as in Kenya, East Africa
[16], in Madagascar [19], Equatorial Guinea and Angola,
African West Coast [20] and Mauritania, north-western
Africa [21]. Moreover, the data obtained in the population
of Anajás are in accordance with those found in children
from Madagascar [19], where in individual study sites with
sufficient numbers of PCR-positive P. vivax infections to
enable comparisons, prevalence ratios were not signifi-
cantly different between Duffy-positive and -negative chil-
dren. That is, the risk of malaria infection due to P. vivax
was not different between the Duffy-negative and Duffy-
positive groups.
It is of note that other genotypes besides Duffy-negative
have been shown capable of influencing the susceptibility
to P. vivax infection [18,25], but this was not observed in
Anajás, since the genotype frequencies did not differin the population of Anajás, State of Pará, Brazil
ntrols* P. vivax-infecteds p-value
(28.6%) 12 (30.0%) 0.9955
(33.4%) 10 (25.0%) 0.3735
(13.8%) 7 (17.5%) 0.6983
(12.4%) 7 (17.5%) 0.5188
(8.3%) 4 (10.0%) 0.9488
(3.4%) 0 (0.0%) 0.4835
(20.1%) 5 (22.7%) 0.9973
(30.6%) 4 (18.2%) 0.3473
(14.6%) 3 (13.6%) 0.8354
(13.2%) 4 (18.2%) 0.7647
(18.1%) 4 (18.2%) 0.7771
(3.5%) 2 (9.1%) 0.5145
(24.0%) 8 (25.0%) 0.9144
(19.3%) 7 (21.9%) 0.9336
(19.3%) 5 (15.6%) 0.8112
(16.0%) 4 (12.5%) 0.8194
(13.3%) 8 (25.0%) 0.1643
(8.0%) 0 (0.0%) 0.2065
(25.3%) 26 (26.5%) 0.2106
(29.1%) 22 (22.4%) 0.8606
(15.5%) 15 (15.3%) 0.6765
(13.4%) 16 (16.3%) 0.9430
(11.9%) 17 (17.3%) 0.0662
(4.7%) 2 (2.0%) 0.2634
Table 2 Allelic frequencies of the Duffy blood group
system and Plasmodium species diagnosis in in the
population of Anajás, State of Pará, Brazil
Place Alelles Controls* P. vivax-infecteds p-value
City of Anajás FY*A 303 (52.2%) 41 (51.3%) 0.9625
FY*B 193 (33.3%) 28 (35.0%) 0.8572
FY*BES 84 (14.5%) 11 (13.8%) 0.9959
Vencedora FY*A 123 (42.7%) 17 (38.6%) 0.7297
FY*B 108 (37.5%) 16 (36.4%) 0.9823
FY*BES 57 (19.8%) 11 (25.0%) 0.5507
Luciana FY*A 130 (43.3%) 28 (43.8%) 0.9380
FY*B 97 (32.3%) 23 (35.9%) 0.6815
FY*BES 73 (24.3%) 13 (20.3%) 0.5993
Total population FY*A 553 (47.7) 89 (45.4) 0.5378
FY*B 394 (34.0) 71 (36.2) 0.5571
FY*BES 213 (18.4) 36 (18.4) 0.9986
*patients infected with P. falciparum and non-infected individuals.
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patients both in the whole sample and in each site investi-
gated. One possible explanation for the results obtained in
Anajás would be that the intensity of transmission of P.
vivax in this region is such that it provides a constant
source of parasites that infect Duffy-positives, providing
ample opportunities for infection of hepatocytes Duffy-
negative and selecting strains of P. vivax with a new
capacity to invade erythrocytes, possibly through a
Duffy-independent mechanism. In this scenario, less
prominent protective effects against infection by P. vivax
conferred by other genotypes seem to have been abolished
or are less evident.
This study was unable to assess possible effects of
Duffy genotypes on the risk of developing clinical ma-
laria, since the patients were not followed after medical
attention. Anyway, it is important to note that only one
of the two Duffy-negative patients diagnosed as P. vivax-
infected through mtDNA-qPCR method was confirmed
by microscopic examination of blood smear, and had
parasitemia classified as low (12 parasites per field under
oil immersion microscope). The other patient was only
detected by qPCR, but also presented a profile consis-
tent with low parasitemia. In addition, with respect to
clinical manifestations, both were asymptomatic at the
time of medical consultation.
The observed frequencies of Duffy-negative genotype in
P. vivax patients and controls in Anajás population (2.1%
and 4.6%, respectively), which are not significantly different,
are smaller than those found in Afro-Brazilian communities
in eastern Amazonia (Pará and Amapá) [26], in which the
genotype frequencies ranged from 0.323 to 0.588, but are
quite similar to those found in most Amazonian popula-
tions already studied (frequencies ranging from 0 to 12%)[17,18,27,28]. Moreover, the frequencies of Duffy genotypes
found in Anajás are the expected for a population with a
genetic background resulting from the admixture between
Europeans, mainly Portuguese, Africans and Amerindians
in very close proportions [29]. Thus, the observed distribu-
tion of Duffy genotypes in the population of Anajás with a
high frequency of Duffy-positive associated with a high
prevalence of malaria, predominantly P. vivax, appears to
fulfil the conditions considered by Ménard et al [19] as ne-
cessary to clear the barrier of Duffy negativity, providing
conditions for the parasites have sufficient exposure to
Duffy-negative red cells, allowing more opportunities for
de novo selection or optimization of an otherwise cryptic
invasion pathway that nevertheless seems less efficient than
the Duffy-dependent pathway.Conclusions
The data obtained in the population of Anajás showed
no differential resistance to P. vivax infection among
Duffy-negative and Duffy-positive, a result that needs to
be corroborated by further evaluation in a larger sample
of patients with P. vivax malaria, and by molecular
characterization of the parasite in order to evaluate the
diversity of strains of P. vivax circulating in this area,
coupled with the ability to invade erythrocytes using
other receptors than Duffy. However, this result could
mean that new capacity of the parasite may be relatively
common in the population of Anajás through adaptive
mechanisms and evolutionary processes that deserve to
be investigated, and that this genetic profile of the para-
site, resulting in the loss of an important protective
mechanism against vivax malaria, may be contributing
significantly to increase the susceptibility to infection by
P. vivax and, consequently, to the high incidence of
malaria in the municipality of Anajás.
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